RIST4721 FOR TREATMENT OF SERIOUS IMMUNE-MEDIATED INFLAMMATORY DISEASES
Arena and Aristea Therapeutics, Inc. established a strategic collaboration and option agreement to advance the clinical development of RIST4721, an oral CXCR2 antagonist being developed by Aristea for the treatment of palmoplantar pustulosis (PPP) and other neutrophil-mediated diseases. Under the terms of the agreement, Arena provided a $60 million upfront payment to Aristea and a $10 million equity investment in Aristea’s Series B financing. In return, Aristea has granted Arena an exclusive option to acquire Aristea, including rights to all CXCR2 programs, upon completion of the Phase 2b study of RIST4721 in PPP. The agreement also provides a framework during the option period for the companies to jointly explore the development of additional neutrophil-mediated diseases, including hidradenitis suppurativa (HS) and inflammatory bowel disease (IBD), potentially generating multiple data readouts during the option period.
RaLinepag For Pulmonary Arterial Hypertension (PAH)
Arena and United Therapeutics entered into an Exclusive License Agreement related to ralinepag, which is currently being evaluated for treatment of PAH. Under the agreement, we granted United Therapeutics an exclusive, global, perpetual, irrevocable license to develop, manufacture, and commercialize ralinepag in any formulation for any indication. United Therapeutics will be responsible for development, manufacture, and commercialization of the investigational product. In addition to an upfront payment of $800 million we received from United Therapeutics upon closing, we are also eligible to receive up to an aggregate of $400 million in regulatory milestone payments related to ralinepag, as well as low, double-digit, tiered royalties on net sales of ralinepag, subject to certain adjustments for third party license payments.
Etrasimod In Greater China And Select Asian Countries
Arena and Everest Medicines have a development and commercialization partnership for investigational drug candidate etrasimod in mainland China, Taiwan, Hong Kong, Macau, and South Korea (the "Territories"). The goal is to leverage Everest capabilities in the evolving regulatory landscape in China to gain approval of transformative foreign drugs. Under the terms of the agreement, Arena has granted Everest exclusive rights to develop and commercialize etrasimod in the Territories. In return, Arena will receive an upfront payment and is eligible to receive, develop, and commercialize milestone payments as well as royalties on net annual sales of etrasimod. The parties plan to collaborate on development of both investigational products; however, Everest is generally responsible for funding development and commercialization in the Territories.
Undisclosed GPCR Orphan Candidate
Arena and Boehringer Ingelheim have a Research and Licensing Agreement to conduct joint research to identify drug candidates to GPCR that belong to the group of orphan CNS receptors. The goal is to identify additional drug candidates that are suitable for continued research and development as therapeutic compounds for various disease indications, with the initial focus expected to be on psychiatric disease such as schizophrenia. The agreement grants Boehringer Ingelheim exclusive worldwide rights to develop, manufacture, and commercialize products resulting from the collaboration.
Etrasimod is an investigational drug and is not currently approved for use by any health authority.